



SLx-2119

Catalog No: tcsc0776

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications Specifications
CAS No: 911417-87-3
Formula: $C_{26}^{H}_{24}^{N}_{6}^{O}_{2}$
Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage
Target: ROCK;ROCK;
Purity / Grade: >98%
Solubility: DMSO : ≥ 29 mg/mL (64.09 mM)
Alternative Names: ROCK inhibitor;KD-025
Observed Molecular Weight: 452.51



Product Description

SLx-2119 is a selective inhibitor of **ROCK2** with IC_{50} of 105 nM, more than 200 fold selectivity over ROCK1 (IC_{50} =24 μ M).

IC50 & Target: IC50: 105 nM (ROCK2)^[1]

In Vitro: SLx-2119 (40 μ M) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. The microarray hybridized with aRNA from HMVEC treated with SLx-2119, shows a 5-times higher background than the other arrays^[1].

In Vivo: KD025 (100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. KD025 is at least as efficacious in aged, diabetic or female mice, as in normal adult males^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!